New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy

Kidney Int. 2015 Jan;87(1):17-9. doi: 10.1038/ki.2014.354.


The best initial therapy for steroid-sensitive nephrotic syndrome (SSNS) in children is subject to ongoing debate. Systematic reviews and meta-analyses have concluded that at least 3 months and up to 7 months of treatment would reduce the number of relapses by 30%. But summarizing small underpowered studies cannot eliminate the basic flaws in design. Two well-powered randomized prospective trials now come to the opposite conclusion, and these results should impact the management of children with SSNS.

Publication types

  • Comment

MeSH terms

  • Female
  • Glucocorticoids / administration & dosage*
  • Humans
  • Male
  • Nephrotic Syndrome / drug therapy*
  • Prednisolone / administration & dosage*


  • Glucocorticoids
  • Prednisolone